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Introduction {#sec001}
============

Reactivation of hepatitis B virus (HBV) is a well-known complication in chronic hepatitis B patients receiving immunosuppressive therapy \[[@pone.0201316.ref001]\]. HBV reactivation can lead to asymptomatic increase of serum transaminase levels and acute hepatic failure \[[@pone.0201316.ref002]\]. Thus, it is clinically important to prevent HBV reactivation in cancer patients. HBV reactivation in cancer patients receiving cytotoxic chemotherapy can lead to premature termination of chemotherapy or delay in treatment schedules \[[@pone.0201316.ref003]\].

Recently, it has been reported that HBV reactivation can occur in hepatocellular carcinoma (HCC) treatment such as transarterial chemoemblization (TACE), resection, and radiofrequency ablation (RFA) \[[@pone.0201316.ref004]--[@pone.0201316.ref006]\]. HBV reactivation after TACE in HCC treatment has been well-studied. It has been reported that HBV reactivation can occur in 4%--40% of patients undergoing TACE treatment \[[@pone.0201316.ref004], [@pone.0201316.ref007], [@pone.0201316.ref008]\]. HBV reactivation has also been observed in 15.5%--27.7% of patients after surgical resection of hepatocellular carcinoma \[[@pone.0201316.ref005], [@pone.0201316.ref009], [@pone.0201316.ref010]\]. Previous study has suggested that RFA can reactivate HBV replication. However, the incidence of HBV reactivation after RFA is relatively lower (5.6%) than that after hepatic resection (14.0%) \[[@pone.0201316.ref006]\]. HBV reactivation during HCC treatment can affect liver function and survival \[[@pone.0201316.ref010]--[@pone.0201316.ref012]\]. To reduce HBV reactivation and reserve liver function after TACE, resection, and RFA, antiviral therapy is very important. Radiotherapy (RT) was infrequently performed for HCC due to radiation induced liver disease (RILD) \[[@pone.0201316.ref013]\]. There is no effective treatment after the development of RILD. Recently, RT has been used to treat patients with HCC who are ineligible for loco-regional therapy \[[@pone.0201316.ref014], [@pone.0201316.ref015]\]. With advances in radiation technology, RILD after RT treatment is tolerable \[[@pone.0201316.ref016]\]. However, the risk of HBV reactivation after RT in HCC patients remains unclear.

Thus, the objective of this study was to determine the incidence and risk factors of HBV reactivation after RT in HCC patients. We also evaluated the effect of antiviral therapy on HBV reactivation and clinical outcome correlated with HBV reactivation.

Materials and methods {#sec002}
=====================

Patients {#sec003}
--------

Between March 2009 and February 2016, HCC patients treated with RT at seven centers were reviewed in this retrospective study. All patients underwent tests for HBsAg, antibody to HBsAg (anti-HBs), hepatitis B e antigen (HBeAg), antibody to HBeAg (anti-HBe), antibody to hepatitis B core antigen (anti-HBc), serum HBV DNA quantification, liver function (alanine aminotransferase \[ALT\], ALP, total bilirubin, and albumin, prothrombin time) before and after RT. We excluded the following patients: 1) HBsAg negativity; 2) evidence of co-infection with human immunodeficiency virus and hepatitis C virus; 3) loss to follow-up within 3 months after RT; 4) No available HBV DNA quantification before and after RT; 5) history of glucocorticoid and immunotherapy. All patients were followed up at intervals of less than 3 months. Post RT HBV DNA levels were checked during follow-up less than 3 months. Initial HBV DNA levels after RT were checked in 17 patients at 0--1 months, 46 patients at 1--2 months, and 70 patients at 2--3 months.

A total of 464 patients received RT for HCC. Among these, we excluded 179 HBsAg negative patients. Of the remaining 285 patients, 152 patients were excluded from analysis due to no available HBV DNA level, follow-up loss, or poor data integrity within 3 months after the RT. Finally, a total of 133 patients with HBV-HCC were enrolled in the study. This study was approved by the Institutional Review Board of each tertiary center (reference number: 2016-06-13) and written informed consent was waived because of the retrospective study.

Radiotherapy {#sec004}
------------

RT was considered for patients who had post TACE progression or was not eligible for resection or RFA. RT was performed by two methods: conventional RT (CRT) and stereotactic body RT (SBRT). In CRT, three-dimensional conformal radiotherapy was usually used to treat medium- or large-sized HCC. Each patient received a daily fraction of 1.8--2.0 Gy up to a total dose of 45--64 Gy in five fractions per week up to 25--32 fractions. In SBRT, the total dose administered was 40--60 Gy in three to five fractions over consecutive days or twice a week to treat small-sized HCC.

Antiviral therapy {#sec005}
-----------------

Antiviral therapy was carried out according to the Korean Association for the Study of the Liver (KASL) guideline \[[@pone.0201316.ref017]\]. Antiviral therapy was administered in the HCC patients who had an ALT \> upper limit of normal (UNL) (\>40 IU/L) and detectable levels of HBV DNA (\>20 IU/ml). Patients who had ALT \< UNL or undetectable levels of HBV DNA were performed RT without antiviral treatment. Patients were divided into two groups based on antiviral treatment during RT: 1) antiviral group, patients with antiviral treatment during RT; and 2) non-antiviral group, patients without antiviral treatment during RT. Four types of oral antiviral drugs were used: 100mg lamivudine (Heptodin, GlaxoSmithkline), 10mg adefovir dipivoxil (Hepsera GlaxoSmithkline), 0.5mg entecavir (Baraclude, Sino-American Squibb Pharmaceuticals) and 300mg tenofovir (Viread, Gilead Sciences).

Definition {#sec006}
----------

HBV reactivation was defined as a \>10-fold increase in HBV DNA level compared to baseline or the appearance of HBV DNA from an undetectable level at baseline and a post-treatment HBV DNA \> 200 IU/mL \[[@pone.0201316.ref004]\]. Hepatitis was defined as a threefold or more increase in serum ALT level above the upper limit of normal (\< 40 IU/L) or an absolute increase of ALT to more than 100 IU/L. RILD was defined as worsening of Child-Pugh (CP) score by 2 or more within 3 months after RT \[[@pone.0201316.ref018]\]. Hepatitis attributed to HBV reactivation was defined as the presence of hepatitis in patients with HBV reactivation. RILD attributed to HBV reactivation was defined as the presence of RILD in patients with HBV reactivation. TACE combined with RT was defined as performing RT within 4 weeks after TACE \[[@pone.0201316.ref019]\].

Statistical analyses {#sec007}
--------------------

Baseline data were analyzed using Student's *t*-test, Chi-square test, and Fisher's exact test when appropriate. Univariate analysis and multivariate analysis using logistic regression model were performed to identify risk factors for HBV reactivation. Data were analyzed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

Results {#sec008}
=======

Patient characteristics {#sec009}
-----------------------

A total of 133 HCC patients were treated with RT in this study, including 106 patients who received antiviral treatment during RT (antiviral group) and 27 patients who did not receive antiviral treatment during RT (non-antiviral group). Of the 106 patients who received antiviral treatment, 18 received lamivudine 100 mg per day, 6 received adefovir dipivoxil 10 mg per day, 9 took lamivudine 100 mg with adefovir dipivoxil 10 mg per day, 52 took entecavir 0.5 mg per day, and 21 took tenofovir 300 mg per day. There were no significant differences in baseline characteristics between the antiviral group and the non-antiviral group. Baseline characteristics of these 133 patients are summarized in [Table 1](#pone.0201316.t001){ref-type="table"}.

10.1371/journal.pone.0201316.t001

###### Baseline characteristics of patients in the antiviral group and the non-antiviral group.

![](pone.0201316.t001){#pone.0201316.t001g}

  --------------------------------------------------------------------------------------
  Variable                          Antiviral group\    Non-antiviral group\   P value
                                    (n = 106)           (n = 27)               
  --------------------------------- ------------------- ---------------------- ---------
  Sex                                                                          

   Male/Female                      83/23               22/5                   0.718

  Age (Year)                        58.8 ± 9.7          57.3 ± 6.6             0.455

  ALT                               42.5 ±34.5          33.0 ± 19.9            0.171

  AFP (median)                      32.4 (1--3328000)   45.0 (2.03--4640000)   0.367

  HBeAg                                                                        

   Positive/negative                20/86               3/24                   0.341

  HBV DNA (IU/ml)                                                              

   \>2000/ \<2000                   26/80               8/19                   0.354

  Child pugh class                                                             

   A/B                              87/19               26/1                   0.065

  Radiotherapy type                                                            

   CRT/SBRT                         67/39               16/11                  0.705

  Radiation dose (Gy)               48.8 ± 0.7          48.1 ± 1.0             0.716

  Combination treatment with TACE                                              

   Yes/No                           48/58               10/17                  0.440

  Tumor size                        4.3 ± 3.8           5.2± 4.2               0.295
  --------------------------------------------------------------------------------------

Values are presented as median (range), or mean ± SD.

ALT, alanine aminotransferase; HBV, Hepatitis B virus; AFP, a-fetoprotein; CRT, conventional radiotherapy; SBRT, Stereotactic body radiotherapy; TACE, transarterial chemoembolization.

Clinical outcomes between patients with or without antiviral treatment {#sec010}
----------------------------------------------------------------------

HBV DNA reactivation occurred in 17 (12.7%) of 133 patients after RT. Mean duration of HBV reactivation after RT was 2.3 ± 0.7 months. Those who received antiviral treatment showed lower incidence of HBV reactivation compared to those who received no antiviral treatment (7.5% \[8/106\] vs. 33.3% \[9/27\], *P*\<0.001). Incidence rate of hepatitis was 16.0% (17/106) in the antiviral group and 29.6% (8/27) in the non-antiviral group (*p* = 0.107). The incidence rate of hepatitis due to HBV reactivation was lower in the antiviral group than that in the non-antiviral group (3.8% \[4/106\] vs. 14.8% \[4/27\], *P* = 0.031). Incidence rate of RILD was 14.2% (15/106) in the antiviral group and 18.5% (5/27) in the non-antiviral group (*P* = 0.571). Incidence rates of RILD due to HBV reactivation were not significantly different between the non-antiviral group and the antiviral group (4.7% \[5/106\] vs. 7.4% \[2/27\], *P* = 0.576) ([Table 2](#pone.0201316.t002){ref-type="table"}). The duration of antiviral treatment before RT is 21.4 (±21.8) months in patients with HBV reactivation and 22.6 (±21.6) months in patients without HBV reactivation (*P* = 0.882).

10.1371/journal.pone.0201316.t002

###### Clinical outcomes for HBV reactivation.

![](pone.0201316.t002){#pone.0201316.t002g}

  -------------------------------------------------------------------------------------------------
                                  Antiviral group\   Non-antiviral group\   Total\       P value
                                  (n = 106)          (n = 27)               (n = 133)    
  ------------------------------- ------------------ ---------------------- ------------ ----------
  All cases of HBV reactivation   8 (7.5%)           9 (33.3%)              17 (12.7%)   \< 0.001

  All cases of Hepatitis          17 (16.0%)         8 (29.6%)                           0.107

   HBV reactivation               4 (3.8%)           4(14.8%)                            0.031

   Other causes                   13 (12.3%)         4 (14.8%)                           0.723

  All cases of RILD               15 (14.2%)         5 (18.5%)                           0.571

   HBV reactivation               5 (4.7%)           2 (7.4%)                            0.576

   Other causes                   10 (11.1%)         3 (9.4%)                            0.793
  -------------------------------------------------------------------------------------------------

HBV, hepatitis B virus; RILD, radiation induced liver disease.

Predictive factors of HBV DNA reactivation after RT {#sec011}
---------------------------------------------------

In univariate analysis, age, gender, Child-pugh class, HBeAg status, pretreatment HBV DNA level, or type of RT did not affect HBV reactivation. Only non-antiviral therapy and combined treatment of RT with TACE correlated significantly with HBV DNA reactivation after RT. Multivariate analysis using logistic regression model revealed that non-antiviral treatment (OR: 8.339, 95% CI: 2.532--27.470, p\<0.001) and combined treatment of RT with TACE (OR: 5.313, 95% CI: 1.548--18.232, p = 0.008) were associated with HBV reactivation ([Table 3](#pone.0201316.t003){ref-type="table"}).

10.1371/journal.pone.0201316.t003

###### Risk factors related to HBV reactivation during radiotherapy.

![](pone.0201316.t003){#pone.0201316.t003g}

                                    Univariate analysis   Multivariate analysis                                   
  --------------------------------- --------------------- ----------------------- ------- ------- --------------- ---------
  Age (year)                        1.006                 0.951--1.063            0.839                           
  Gender                                                                                                          
  Male/Female                       0.848                 0.253--2.836            0.789                           
  ALT (IU/L)                        1.004                 0.990--1.018            0.600                           
  Child-pugh class                                                                                                
   A                                1.000                                                                         
   B                                0.319                 0.040--2.552            0.282                           
  Antiviral treatment                                                                                             
   Yes                              1.000                                                                         
   No                               6.125                 2.087--17.980           0.001   8.339   2.532--27.470   \<0.001
  Combination treatment with TACE                                                                                 
   No                               1.000                                                                         
   Yes                              3.652                 1.206--11.056           0.022   5.313   1.548--18.232   0.008
  HBeAg                             1.000                                                                         
  Positive/ Negative                0.603                 0.128--2.840            0.522                           
  Pretreatment HBV DNA (IU/ml)                                                                                    
   ≥2000                            1.000                                                                         
   \< 2000                          0.322                 0.070--1.483            0.146                           
  Radiotherapy type                                                                                               
   CRT                              1.000                                                                         
   SBRT                             0.639                 0.229--1.779            0.391                           
  Radiation dose (Gy)               1.000                 1.000--1.000            0.993                           
  AFP                                                                                                             
   \< 200                           1.000                                                                         
   ≥200                             1.825                 0.653--5.102            0.252   1.553   0.499--4.833    0.448

OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; HBV, Hepatitis B virus; TACE, transarterial chemoembolization; CRT, conventional radiotherapy; SBRT, Stereotactic body radiotherapy; AFP, a-fetoprotein.

HBV reactivation in subgroups {#sec012}
-----------------------------

Incidences of HBV reactivation were analyzed depending on whether patients received combined TACE treatment before RT. Results are shown in [Fig 1](#pone.0201316.g001){ref-type="fig"}. 58 patients received combined treatment of RT with TACE (RT-TACE group) and 75 received RT alone (RT group). There was a significantly higher incidence of HBV reactivation in RT-TACE group than RT group (20.7% \[12 of 58\] vs. 6.7% \[5 of 75\], *P* = 0.016).

![Subgroup analysis according to risk factor related to HBV reactivation during radiotherapy.](pone.0201316.g001){#pone.0201316.g001}

We also analyzed the effect of antiviral treatment in both RT and RT-TACE groups. In the RT group, the incidence of HBV reactivation was 0% (0 of 58 patients) in those who received antiviral treatment and 29.4% (5 of 17 patients) in those who received no antiviral treatment (*p* \< 0.001). In the RT-TACE group, the incidence of HBV reactivation was 16.7% (8 of 48 patients) in those who received antiviral treatment and 50.0% in those who received no antiviral treatment (5 of 10 patients) (*P* = 0.098).

Clinical features of patients who had HBV reactivation after RT {#sec013}
---------------------------------------------------------------

A total of 21 patients developed HBV DNA reactivation after RT. However, four patients were excluded because the HBV reactivation was due to drug resistance. Clinical features of the remaining 17 patients who developed HBV reactivation after RT are summarized in [Table 4](#pone.0201316.t004){ref-type="table"}.

10.1371/journal.pone.0201316.t004

###### Clinical features of 17 patients with HBV reactivation after radiotherapy.
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              Treatment                  Baseline   Follow up   At the time of reactivation                                                                 
  ---- ------ -------------------------- ---------- ----------- ----------------------------- ---- ---- ------- --- ----- ----- ------ --------- ---- ----- -----
  1    M/47   Lamivudine                 Yes        CRT         5040                          \-   38   \< 20   5   2.8   5.6   75     461       5    No    No
  2    F/59   Lamivudine                 Yes        CRT         5000                          \-   16   \< 20   6   1.2   3.8   155    721       10   Yes   Yes
  3    M/54   Lamivudine                 Yes        SBRT        4500                          \-   20   1220    5   2.1   2.1   522    58460     8    Yes   Yes
  4    M/64   Adefovir with lamivudine   Yes        CRT         5000                          \-   23   \<20    8   0.8   0.8   241    159       11   Yes   Yes
  5    M/69   Adefovir                   Yes        SBRT        5200                          \-   57   \<20    5   1.7   1.7   39     415       7    No    Yes
  6    M/73   Entecavir                  Yes        CRT         4500                          \+   13   23      5   0.6   3.7   58     1700000   5    Yes   No
  7    F/71   Lamivudine                 Yes        CRT         4500                          \-   42   \<20    5   2.9   2.9   39     422       6    No    No
  8    F/61   Entecavir                  Yes        CRT         4500                          \-   26   \<20    5   1.6   1.6   32     144       8    No    Yes
  9    M/50   No                         Yes        CRT         5000                          \-   14   1781    5   1.1   3.1   158    1000000   5    Yes   No
  10   M/44   No                         Yes        SBRT        5400                          \-   60   3970    5   1.2   1.2   32     135900    9    No    Yes
  11   M/50   No                         No         SBRT        4800                          \-   17   1080    5   1.7   1.7   35     89200     5    No    No
  12   M/70   No                         No         SBRT        6000                          \-   17   873     5   0.7   0.7   33     155000    6    No    No
  13   F/64   No                         No         CRT         2700                          \-   35   \<20    5   1.0   1.0   166    2981      10   Yes   Yes
  14   M/55   No                         No         CRT         5600                          \-   13   146     6   2.5   2.5   363    52675     5    Yes   No
  15   M/54   No                         Yes        CRT         4000                          \-   64   \<20    5   1.8   1.8   1316   257       6    Yes   No
  16   M/54   No                         Yes        SBRT        4500                          \+   56   25      5   1.4   1.4   67     16200     5    No    No
  17   M/63   No                         No         SBRT        5040                          \-   86   20.8    5   1.1   4.2   15     2610      6    No    No

TACE, transarterial chemoembolization; RT, radiotherapy; HBV, Hepatitis B virus; ALT, alanine aminotransferase; CP, child pugh; CRT, conventional radiotherapy; SBRT, Stereotactic body radiotherapy; RILD, radiation induced liver disease.

Discussion {#sec014}
==========

Our study showed that HBV reactivation could occur after RT. The incidence rate of HBV reactivation was 7.1% in the antiviral group and 31.0% in the non-antiviral group (*P*\<0.001, [Table 2](#pone.0201316.t002){ref-type="table"}). We reported that mean duration of HBV reactivation after RT was 2.3 months. This result might be due to the fact that most patients underwent HBV DNA measurement within 2--3 months after RT. Kim et al. first reported HBV reactivation after RT. The cumulative rate of HBV reactivation was 21.8% (7 of 32) in patients who underwent conformal RT without lamivudine therapy \[[@pone.0201316.ref020]\]. However, their study had limitation in that their sample size was too small. In a study of Huang et al., the incidence rate of HBV reactivation without antiviral treatment was 24.6% at the end of conformal RT \[[@pone.0201316.ref021]\]. Pathogenesis of RT induced HBV reactivation remains uncertain. According to previous studies, HBV reactivation induced by RT is considered a bystander effect due to cytokines such as IL-6 released by irradiated endothelial cells while IL-6 can induce HBV reactivation through signal transduction pathway \[[@pone.0201316.ref022], [@pone.0201316.ref023]\]. These results suggest that HBV reactivation can occur after RT and antiviral treatment can reduce HBV reactivation after RT.

This study demonstrated that antiviral therapy could reduce the incidence of hepatitis due to HBV reactivation after RT. Hepatitis due to HBV reactivation was significantly lower in the antiviral group compared to that in the non-antiviral group (3.8% \[4/106\] vs. 14.8% \[4/27\], *P* = 0.031, [Table 2](#pone.0201316.t002){ref-type="table"}). This suggests that antiviral treatment can prevent hepatitis after RT. It has been reported that preventive antiviral treatment in HBV-HCC patients can reduce side effects after or during HCC treatment and preserve liver function \[[@pone.0201316.ref004], [@pone.0201316.ref010], [@pone.0201316.ref024], [@pone.0201316.ref025]\]. In a previous study, lamivudine therapy reduced HBV reactivation, hepatitis due to HBV reactivation, and hepatic morbidity during TACE \[[@pone.0201316.ref004]\]. In a prospective study, Xu et al. have suggested that lamivudine therapy could reduce HBV activation (11.2% vs. 45.6%, *P*\<0.001) and improve survival of HCC patients treated with TACE (relative risk = 0.423; 95% CI: 0.248--0.721, *P* = 0.002) \[[@pone.0201316.ref025]\]. Chen et al. have also reported that patients in the antiviral group have faster (*P* = 0.016) recovery of albumin level \[[@pone.0201316.ref010]\]. In a randomized control trial, antiviral therapy increased liver function recovery (hazard ratio: 1.23; 95% CI: 0.98--2.55; p = 0.109) \[[@pone.0201316.ref024]\]. These studies demonstrate that antiviral treatment can reduce treatment-related side effects in patients with HCC. Therefore, antiviral therapy is effective in reducing the risk of HBV reactivation and hepatitis due to HBV reactivation in HCC patients receiving RT.

Our results showed that combined treatment of TACE with RT and non-antiviral treatment were significantly correlated with HBV reactivation in multivariate analysis ([Table 3](#pone.0201316.t003){ref-type="table"}). First, combined treatment of TACE with RT increased the risk of HBV reactivation compared to RT alone (OR: 5.313, 95% CI: 1.548--18.232, p = 0.008), consistent with results of previous studies \[[@pone.0201316.ref026]\]. In a Korean study, there was a significant trend of increased risk of reactivation with increasing intensity of therapy, with hazard ratio of 1.0 for local ablation therapy, 2.45 for TACE (using Adriamycin), 4.19 for TACE (using cisplatin), and 10.17 for TACE (using cisplatin) with RT \[[@pone.0201316.ref026]\]. HBV reactivation was also higher in hepatic resection than that in local treatment. Dan et al. have reported that the incidence of HBV reactivation after RFA is relatively lower compared to that after hepatic resection (5.6% vs. 14.0%, p = 0.034) \[[@pone.0201316.ref006]\]. These results suggest that treatment intensity is correlated with the risk of HBV reactivation. Second, non-antiviral treatment before RT was also associated with high risk of HBV reactivation after RT (OR: 8.339, 95% CI: 2.532--27.470, p\<0.001). This result has been well documented in other treatment modalities. Non-antiviral treatment has been reported to be an independent factor for increased risk of HBV reactivation after TACE \[[@pone.0201316.ref004], [@pone.0201316.ref009], [@pone.0201316.ref025]\] and after resection \[[@pone.0201316.ref005], [@pone.0201316.ref010], [@pone.0201316.ref024]\]. Therefore, non-antiviral therapy and combined treatment of RT with TACE are important risk factor for HBV reactivation in patients receiving RT.

We performed subgroup analysis depending on whether patients received combined TACE treatment before RT. Results are shown in [Fig 1](#pone.0201316.g001){ref-type="fig"}. The incidence of HBV reactivation was significantly higher in the combined RT-TACE group compared to that in the RT group (20.7% vs. 6.7%, *P* = 0.016). In the RT group, HBV reactivation did not occur during antiviral treatment. The incidence rate of HBV reactivation in patients without antiviral treatment was 29.4%, similar to results reported in previous studies \[[@pone.0201316.ref020], [@pone.0201316.ref021]\]. Interestingly, the rate of HBV reactivation was 16.7% during antiviral treatment in the TACE-RT group. However, HBV reactivation recovered spontaneously without hepatitis. The rate of HBV reactivation was the highest in patients without antiviral treatment in the TACE-RT group.

This study has some limitations. First, this was a retrospective study. Second, the sample size for the non-antiviral group was small, although we analyzed data from seven institutions. However, we analyzed a large number of patients compared to previous studies. We also analyzed clinical factors to predict HBV reactivation. Third, we did not demonstrate the effect of antiviral therapy on survival in patients with RT. Fourth, we did not show when HBV DNA was reactivated because the timing of HBV measurement after RT was not the same.

In conclusion, HBV reactivation that causes hepatitis can occur after RT in HCC patients. Combined treatment of RT with TACE and non-antiviral treatment are major risk factors for HBV reactivation during RT. Antiviral therapy can reduce HBV reactivation and complications after RT. Therefore, preventive antiviral therapy should be recommended for patients with HCC who are scheduled to receive RT.

Supporting information {#sec015}
======================

###### 

(XLSX)

###### 

Click here for additional data file.

###### Dataset of reactivation duration.

(XLSX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
